Trial Profile
A phase II study of Temsirolimus in patients with advanced hormone - and chemotherapy - resistant prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2017
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 28 Apr 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 06 Oct 2011 New trial record